Squarepoint’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Squarepoint’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,654	Closed	-$25K	–	2826
2019 Q2	$25K	Buy	+2,654	New	+$48.8K	﹤0.01%	2311
2018 Q3	–	Sell	-1,164	Closed	-$83K	–	2337
2018 Q2	$83K	Buy	+1,164	New	+$82.2K	﹤0.01%	1656
2018 Q1	–	Sell	-3,654	Closed	-$460K	–	2365
2017 Q4	$460K	Buy	3,654 +2,079	+132%	+$266K	0.01%	1260
2017 Q3	$215K	Sell	1,575 -1,308	-45%	-$175K	﹤0.01%	1352
2017 Q2	$411K	Buy	2,883 +2,269	+370%	+$351K	0.01%	1028
2017 Q1	$113K	Sell	614 -419	-41%	-$47K	﹤0.01%	1396
2016 Q4	$83K	Buy	+1,033	New	+$81.7K	﹤0.01%	1651
2016 Q2	–	Sell	-2,947	Closed	-$273K	–	1438
2016 Q1	$273K	Buy	2,947 +1,662	+129%	+$166K	0.02%	866
2015 Q4	$257K	Buy	+1,285	New	+$256K	0.03%	870

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint's TTPH Position: Q3 2019 in Review

Squarepoint sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 2,654 shares — an estimated $25K sold.

Squarepoint first reported a position in TTPH in Q4 2015 and held it in 9 quarters. The position peaked at $460K in Q4 2017. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

Squarepoint reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Squarepoint sold 2,654 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $25K.
Squarepoint first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 9 quarters.
Squarepoint's Tetraphase Pharmaceuticals, Inc. position peaked at $460K in Q4 2017.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Squarepoint's 13F filing for Q3 2019, filed 14 Nov 2019.